AWS CEO: AI could cut drug development time from 15 to 5 years

AI promises to accelerate pharmaceutical innovation

Amazon Web Services CEO Matt Garman believes artificial intelligence could fundamentally transform the pharmaceutical industry's economics by compressing drug development timelines by two-thirds. Speaking on Fox Business's "The Claman Countdown," Garman said AI technology could potentially reduce the time required to bring new drugs to market from 15 years down to just 5 years.

The comments came as Garman discussed AWS's AI-driven drug discovery partnership with Novo Nordisk, the Danish pharmaceutical giant known for diabetes and obesity treatments. The collaboration represents a significant bet by both companies that machine learning and cloud computing can overcome one of the industry's most persistent challenges: the lengthy and expensive process of developing new medications.

Why it matters

Pharmaceutical development timelines directly impact both healthcare costs and patient access to treatments. A 10-year reduction in development cycles would dramatically lower the capital risk for drug companies, potentially enabling more experimental research while bringing life-saving therapies to patients faster. For cloud providers like AWS, healthcare and life sciences represent a major growth opportunity as the industry digitizes research and development infrastructure.

The economics of drug development

Traditional pharmaceutical development involves multiple phases of clinical trials, regulatory reviews, and iterative testing that can span more than a decade. This extended timeline contributes to the high cost of bringing new drugs to market, often estimated at over $2 billion per approved medication when accounting for failed candidates.

AI technologies promise to accelerate several bottlenecks in this process: identifying promising molecular compounds, predicting how drugs will interact with biological systems, optimizing clinical trial design, and analyzing patient data more efficiently. Cloud computing infrastructure enables pharmaceutical companies to run complex simulations and process vast datasets without building expensive on-premise systems.

Cloud giants compete for healthcare workloads

The AWS-Novo Nordisk partnership reflects broader competition among major cloud providers to capture healthcare and life sciences customers. These industries generate massive amounts of data and require significant computational resources for research applications, making them attractive targets for cloud infrastructure companies seeking high-value enterprise clients.

While Garman's 15-to-5-year projection represents an ambitious vision rather than a guaranteed outcome, it signals how technology executives view AI's potential to reshape regulated industries with long development cycles. The actual impact will depend on regulatory acceptance of AI-assisted drug development processes and the technology's ability to maintain safety and efficacy standards.

The details were first reported by Fox Business during Garman's August 14, 2026 appearance on "The Claman Countdown."